EP4406973A1 — Antibodies and uses thereof for the treatment of infections caused by enveloped viruses
Assigned to Institucio Catalana de Recerca i Estudis Avancats ICREA · Expires 2024-07-31 · 2y expired
What this patent protects
The present invention relates to an antibody that specifically binds to sialic acid-binding Ig-like lectin 1 (CD169/Siglec-1), as well as the antigen-binding fragment, the kit and the pharmaceutical composition comprising said antibody. The invention also relates to the use of th…
USPTO Abstract
The present invention relates to an antibody that specifically binds to sialic acid-binding Ig-like lectin 1 (CD169/Siglec-1), as well as the antigen-binding fragment, the kit and the pharmaceutical composition comprising said antibody. The invention also relates to the use of the antibody and the pharmaceutical composition in the prevention and/or the treatment of infection by enveloped virus and, in particular, by an infection by a virus of the filoviridae family, an infection by an Orthopneumovirus, a coronavirus infection or an arenavirus infection.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.